Skip to main content
Nintex logo

Nintex

Security and trust center evidence

nintex.comNo-code and automationLast verified 17 Sep 2026

Summary

Nintex has 3 registry-verified rows in the CertReports index, last verified 17 Sep 2026. The strongest row is FedRAMP: FedRAMP Authorized. This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.

Reviewer brief

As of 17 Sep 2026, Nintex is listed in the FedRAMP registry as FedRAMP Authorized, with the authorization issued 19 Mar 2024 and audited by Lunarline, Inc. As of 17 Sep 2026, Nintex is listed in the CSA STAR registry at STAR Level 1 self-assessment (CAIQ), originally issued 15 Oct 2017. As of 17 Sep 2026, Nintex is listed in the EU-US Data Privacy Framework registry as active across the EU-US Certification, SW-US Certification, and UK Extension Certification, issued 15 Nov 2017 and expiring 12 Aug 2027. As of 17 Sep 2026, no public evidence found for SOC 2 or HIPAA frameworks for Nintex. As of 17 Sep 2026, no subprocessor evidence rows were found for Nintex.

  • FedRAMP: listed in FedRAMP registry as FedRAMP Authorized, issued 19 Mar 2024, auditor Lunarline, Inc. (as of 17 Sep 2026)
  • CSA STAR: listed in CSA STAR registry at Level 1 self-assessment (CAIQ), issued 15 Oct 2017 (as of 17 Sep 2026)
  • EU-US Data Privacy Framework: listed as active (EU-US, SW-US, UK Extension), issued 15 Nov 2017, expires 12 Aug 2027 (as of 17 Sep 2026)

Facts only, each dated; nothing here is inferred, scored or advised. Brief generated 17 Sep 2026; it is regenerated whenever a row changes.

Among no-code and automation vendors

3verified rows

Category median 1, across 61 indexed no-code and automation vendors. Nintex has more verified rows than 100 percent of them.

business processlow-codeprocess automationrpaworkflow management

Compliance grid

Subprocessors

No subprocessor list captured yet.

Similar vendors with evidence

Related by product tags and the No-code and automation category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.